Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
According to Sumeet Jain of Destimoney Securities, one may buy Marico with a target of Rs 289.
Ruchit Jain of Angel Broking is of the view that one may buy Siemens with a target of Rs 1170.
Vijay Chopra of enochventures.com is of the view that one may buy Mawana Sugar with a target of Rs 45.
In an interview to CNBC-TV18 Aashish Tater of fortunewizard.com shared his reading and outlook on fundamental side of the market, specific stocks and sectors.
SP Tulsian of sptulsian.com shares why he is bullish on Globus Spirit and Radico Khaitan. He also runs through key highlights of the Reliance Communications AGM and lists two drug stocks he is interested in.
Amit Harchekar of A Plus Analytics recommends buying Raymond and Radico Khaitan and advises shorting Glenmark Pharma.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy DCB Bank, Radico Khaitan and Canara Bank.
Mayuresh Joshi of Angel Broking is optimistic on Radico Khaitan.
Mayuresh Joshi of Angel Broking is extreamly optimistic on Radico Khaitan with a target of Rs 156 in 12 months.
Chandan Taparia of Anand Rathi Securities is of the view that below Rs 117, Radico Khaitan may test Rs 108-110.
Krish Subramanyam of Altamount Capital advises buying MTNL with a target of Rs 19.90.
SP Tulsian of SP Tulsian.com is of the view that Radico Khaitan looks good at the current level.
Kiran Jadhav of Precision Investment Services is of the view that one may buy Radico Khaitan with a target of Rs 109.
Hemen Kapadia of KR Choksey Securities advises selling Ranbaxy Laboratories with a target of Rs 349 and Mcleod Russel (India) with a target of Rs 278.
According to Hemen Kapadia of KR Choksey Securities, one may buy Asian Paints with a target of Rs 501and Apollo Hospitals with a target of Rs 873.
Larsen and Toubro, Adani Enterprises, Ranbaxy, L&T Finance. NBFCs like IDFC, Power Finance Corporation (PFC). Also REC, UCO Bank ahead of numbers today, Amara Raja, Radico Khaitan after Rakesh Jhunjhunwala bought stake yesterday, KSK Energy Venture and Elpro International.
The research desk at CNBC-TV18 gives a wrap on the reason to watch out for stocks like HDFC, Infosys, L&T, Raymond, Amara Raja, Biocon, M&M Financials, KPIT Technologies, Radico Khaitan and Coromandel Engineering
Krish Subramanium of Asit C Mehta Invstt Intermediates recommends buying Rallis India for a target of Rs 173 and NIIT Technologies for a target of Rs 343.
Nooresh Merani of Analyse India advises buying Chambal Fertiliser for a target price of Rs 43 and Godrej Industries for a target price of Rs 300.
Aashish Tater of Fortunewizard.com is of the view that one may avoid Radico Khaitan.
Lancelot D Cunha of ITI Wealth recommends buying Aurobindo Pharma with a target of Rs 228 and SKS Microfinance.
According to SP Tulsian of sptulsian.com, Radico Khaitan may test Rs 175 in next 30-45 days.
Pankaj Jain of Sunteck Wealthmax Capital advises buying Aurobindo Pharma with a target price of Rs 227 and DB Realty with a target price of Rs 71.50.
Shahina Mukadam of Varun Capital recommends buying Tata Global Beverage with a target of Rs 165 and Radico Khaitan with a target of Rs 156.
Kunal Bothra of LKP advises buying NIIT Technologies with a target price of Rs 312 and Havells India with a target price of Rs 720.